Trials / Completed
CompletedNCT00694798
Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder
Open Label, Single Arm, Exploratory Phase I Clinical Trial to Evaluate Efficacy and Safety of Mycobacterium w (Mw) in BCG Refractory Superficial Transitional Cell Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Cadila Pharnmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the response rate of this treatment (Mw) in patients with BCG refractory superficial transitional cell carcinoma. Other objectives include detecting the effect of Mw on Time to Tumor progression and evaluating safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Mycobacterium w | Immunomodulator |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2008-06-11
- Last updated
- 2012-05-03
Locations
17 sites across 1 country: India
Source: ClinicalTrials.gov record NCT00694798. Inclusion in this directory is not an endorsement.